BNP (B-type Natriuretic Peptide) vs NA-Selank Amidate
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
BNP (B-type Natriuretic Peptide)
BNP is a cardiac neurohormone released primarily by ventricles in response to volume/pressure overload. It's a major biomarker for heart failure and has therapeutic applications as nesiritide.
Full details →NA-Selank Amidate
NA-Selank Amidate (N-Acetyl Selank Amidate) is an enhanced version of Selank with improved stability and blood-brain barrier penetration. The modifications increase bioavailability and duration of cognitive and anxiolytic effects.
Full details →Side-by-Side Comparison
| Aspect | BNP (B-type Natriuretic Peptide) | NA-Selank Amidate |
|---|---|---|
| Mechanism | Similar to ANP - activates NPR-A receptors to produce vasodilation, natriuresis, and RAAS suppression. Released in response to ventricular wall stress. | Same core mechanism as Selank - modulates BDNF, serotonin, and norepinephrine systems. The N-acetyl group improves membrane permeability while the amidate modification increases enzymatic stability. |
| Typical Dosage | Nesiritide (recombinant BNP): 2mcg/kg IV bolus followed by 0.01mcg/kg/min continuous infusion for acute decompensated heart failure. | Intranasal: 100-400mcg 1-3 times daily. Lower doses needed compared to standard Selank due to enhanced bioavailability. |
| Administration | Intravenous administration only. Used in acute care settings for heart failure. BNP levels also used diagnostically. | Primarily intranasal administration. Can be used sublingually. More stable in solution than standard Selank. |
| Side Effects | Hypotension (common and dose-limiting), headache, nausea, and potential renal function worsening in some patients. | Generally well-tolerated. Possible mild fatigue or nasal irritation. Less frequent dosing needed than standard Selank. |
| Best For |